welcome to oneFAPvoice

- a positively charged Familial Adenomatous Polyposis community.
  • join today!
withdrawn

A Trial of Low Dose Sulindac Combined With Eflornithine in Patients With Familial Adenomatous Polyposis (FAP)

key information

study id #: NCT01245816

condition: Familial Adenomatous Polyposis

status: withdrawn

purpose:

The purpose of this phase III study is to evaluate the safety and efficacy of the combination of eflornithine and sulindac compared to single agent sulindac or eflornithine in reducing the number of polyps in patients with familial adenomatous polyposis (FAP).

intervention:
Drug: Eflornithine plus Sulindac
Drug: Eflornithine plus Placebo
Drug: Sulindac plus Placebo

To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences.
More information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close